Research
Hormonal
Tirzepatide demonstrates greater clinical potency than semaglutide, potentially due to glucose-dependent insulinotropic polypeptide (GIP) receptor activation increasing energy expenditure.
If you are struggling with weight loss on a GLP-1 drug like semaglutide, ask your doctor about tirzepatide. It targets two hormones (GIP and GLP-1) instead of just one, which may lead to greater weight loss for some people by increasing how much energy you burn.
ModerateSupportsMEDIUM confidence
He also showed studies suggesting that the greater clinical potency of tirzepatide than of the glucagon-like peptide (GLP)-1 receptor agonist (RA) semaglutide may be an effect of glucose-dependent insulinotropic polypeptide (GIP) receptor activation in increasing energy expenditure.
Why this rating
Based on presentation summaries and 'studies suggesting' rather than a full primary data publication in this text.
Source
The 2023 <scp>WCIRDC</scp>: Obesity
Zachary T. Bloomgarden · Journal of Diabetes · 2024
DOI 10.1111/1753-0407.13568
narrative_reviewCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Aggressive weight loss management is the primary first step for treating type 2 diabetes, as diet can effectively lead to remission through progressively greater degrees of weight loss improving insulin sensitivity.Good
- Time-restricted eating (TRE) with a duration of less than 8 hours per day is associated with an increased risk of cardiovascular mortality.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →